Aktienanalyse zu CRISPR Therapeutics AG (CRSP)CRSPCRISPR Therapeutics AG

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

CRISPR Therapeutics AG is not a good buy right now due to its current price of $49.25, a significantly low RSI of 33.306 indicating oversold conditions, and a troubling year-to-date change of -8.41%. The company is facing substantial losses, with a net income of -91154000 USD in Q2 2026 and a forward P/E ratio of 23.3645, suggesting overvaluation relative to its earnings potential. The main risk is insider selling, which has increased by 476.16% over the last month, indicating a lack of confidence from those closest to the company.

6 analysts cover CRSP: 3 rate it Buy, 3 Hold and 0 Sell. The average price target is 78.89.